All In Biotech

Drug Trial Radar · NCT00556673

Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma

An Exploratory, Multi-centre, Double-blind, Placebocontrolled Crossover Study, to Investigate the Bronchodilatory Efficacy of a Single Dose of Indacaterol in Fixed Combination With Mometasone Furoate Delivered Via a MDDPI (Twisthaler®) in Adult Patients With Persistent Asthma Using Open Label Seretide® Accuhaler® (50/250 Mcg b.i.d.) as an Active Control

Last checked: Nov 19, 2026Latest source record: Apr 22, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

31

Actual

Start

Oct 2007

Primary completion

Apr 2008

Study completion Apr 2008

Sponsor

Lead sponsor
NovartisNovartis (NVS)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Nov 12, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the bronchodilatory efficacy of indacaterol maleate 500 μg/mometasone furoate 400 μg via the Twisthaler® device in adult patients with persistent asthma.

Conditions

  • Asthma

Interventions

  • indacaterol maleate/mometasone furoateDrug

    Indacaterol maleate 250 μg / mometasone furoate 200 μg delivered via the Twisthaler device.

  • placebo to indacaterol maleate/mometasone furoateDrug

    Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.

  • fluticasone proprionate / salmeterol xinafoateDrug

    Fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg delivered via the Accuhaler® device.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Period Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1)Time frame: Pre-dose for each Treatment Period (Days 1, 8 and 15) and 24-hours post-dose for each Treatment Period (Days 2, 9 and 16).

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Novartis Investigator Site

    Poitiers, France

  • Novartis Investigator Site

    Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.